Daunorubicin
- Generic Name
- Daunorubicin
- Brand Names
- Cerubidine, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29NO10
- CAS Number
- 20830-81-3
- Unique Ingredient Identifier
- ZS7284E0ZP
- Background
A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms.
- Indication
For remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.
...
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Chronic Phase Chronic Myeloid Leukemia, Ewing's Sarcoma, Lymphoma, Diffuse, Myeloblastic Leukemia, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Wilms' tumor
- Associated Therapies
- -
Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Conditions
- Interventions
- First Posted Date
- 2016-07-15
- Last Posted Date
- 2021-08-19
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 7
- Registration Number
- NCT02834390
Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement
- Conditions
- Interventions
- Drug: AzacitidineDrug: CyclophosphamideDrug: CytarabineDrug: DaunorubicinDrug: Daunorubicin HydrochlorideDrug: DexamethasoneDrug: Hydrocortisone Sodium SuccinateOther: Laboratory Biomarker AnalysisDrug: LeucovorinDrug: Leucovorin CalciumDrug: MercaptopurineDrug: MethotrexateDrug: PegaspargaseOther: Pharmacological StudyDrug: PrednisoloneDrug: ThioguanineDrug: VincristineDrug: Vincristine Sulfate
- First Posted Date
- 2016-07-11
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 78
- Registration Number
- NCT02828358
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Valley Children's Hospital, Madera, California, United States
🇺🇸Sinai Hospital of Baltimore, Baltimore, Maryland, United States
Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia
- First Posted Date
- 2016-05-18
- Last Posted Date
- 2022-02-18
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 30
- Registration Number
- NCT02776605
- Locations
- 🇪🇸
Hospital Clinic, Barcelona, Spain
🇪🇸Hospital Germans Trias i Pujol, Badalona, Spain
🇪🇸Hospital 12 de Octubre, Madrid, Spain
Modified MRCUKALLⅫ/ECOGE2993 Regimen for ALL
- Conditions
- Interventions
- First Posted Date
- 2016-01-21
- Last Posted Date
- 2017-06-19
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 100
- Registration Number
- NCT02660762
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, GuangZhou, Guangdong, China
Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation
- Conditions
- Interventions
- First Posted Date
- 2015-12-17
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 153
- Registration Number
- NCT02632708
- Locations
- 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
MLN 9708 in Induction and Consolidation for Adults With AML >= 60 Years of Age
- Conditions
- Interventions
- First Posted Date
- 2015-10-21
- Last Posted Date
- 2022-08-24
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 39
- Registration Number
- NCT02582359
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML
- Conditions
- Interventions
- First Posted Date
- 2015-09-25
- Last Posted Date
- 2020-05-05
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 42
- Registration Number
- NCT02560025
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Drug: DasatinibDrug: prednisoneDrug: cyclophosphamideDrug: daunorubicinDrug: vincristineDrug: cytarabineDrug: mercaptopurineDrug: methotrexateDrug: dexamethasoneDrug: mitoxantroneDrug: etoposideProcedure: allogeneic hematopoietic stem cell transplantationProcedure: autologous hematopoietic stem cell transplantation
- First Posted Date
- 2015-08-14
- Last Posted Date
- 2022-08-03
- Target Recruit Count
- 30
- Registration Number
- NCT02523976
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
Treatment of Older Adult Acute Myeloid Leukemia Patients Aged 55 to 65 Years
- First Posted Date
- 2015-05-04
- Last Posted Date
- 2016-10-07
- Lead Sponsor
- Jianxiang Wang
- Target Recruit Count
- 300
- Registration Number
- NCT02432872
- Locations
- 🇨🇳
Treatment and Diagnosis Center of Leukemia, Tianjin, Tianjin, China
Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2015-04-17
- Last Posted Date
- 2018-06-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 1
- Registration Number
- NCT02419469
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.